ANGPT2 and glioblastoma: Dual targeting of Ang-2 and the VEGF pathway reshaped the pro-tumor M2 subtype towards anti-tumor M1 macrophages, thus reducing the tumor burden and mediating survival benefits in glioblastoma [165, 166].